Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC
Compose a Response to This Article
Other responses
No responses have been published for this article.
